110 related articles for article (PubMed ID: 3139281)
1. Increased DNA repair as a mechanism of acquired resistance to cis-diamminedichloroplatinum (II) in human ovarian cancer cell lines.
Masuda H; Ozols RF; Lai GM; Fojo A; Rothenberg M; Hamilton TC
Cancer Res; 1988 Oct; 48(20):5713-6. PubMed ID: 3139281
[TBL] [Abstract][Full Text] [Related]
2. Characterization of a cis-diamminedichloroplatinum(II)-resistant human ovarian cancer cell line and its use in evaluation of platinum analogues.
Behrens BC; Hamilton TC; Masuda H; Grotzinger KR; Whang-Peng J; Louie KG; Knutsen T; McKoy WM; Young RC; Ozols RF
Cancer Res; 1987 Jan; 47(2):414-8. PubMed ID: 3539322
[TBL] [Abstract][Full Text] [Related]
3. Role of carrier ligand in platinum resistance of human carcinoma cell lines.
Schmidt W; Chaney SG
Cancer Res; 1993 Feb; 53(4):799-805. PubMed ID: 8428361
[TBL] [Abstract][Full Text] [Related]
4. Enhanced replicative bypass of platinum-DNA adducts in cisplatin-resistant human ovarian carcinoma cell lines.
Mamenta EL; Poma EE; Kaufmann WK; Delmastro DA; Grady HL; Chaney SG
Cancer Res; 1994 Jul; 54(13):3500-5. PubMed ID: 8012973
[TBL] [Abstract][Full Text] [Related]
5. Increased removal of DNA-bound platinum in a human ovarian cancer cell line resistant to cis-diamminedichloroplatinum(II).
Masuda H; Tanaka T; Matsuda H; Kusaba I
Cancer Res; 1990 Mar; 50(6):1863-6. PubMed ID: 2306738
[TBL] [Abstract][Full Text] [Related]
6. Gene-specific repair of Pt/DNA lesions and induction of apoptosis by the oral platinum drug JM216 in three human ovarian carcinoma cell lines sensitive and resistant to cisplatin.
O'Neill CF; Koberle B; Masters JR; Kelland LR
Br J Cancer; 1999 Dec; 81(8):1294-303. PubMed ID: 10604725
[TBL] [Abstract][Full Text] [Related]
7. Pretreatment with 5-fluorouracil enhances cytotoxicity and retention of DNA-bound platinum in a cisplatin resistant human ovarian cancer cell line.
Tanaka T; Masuda H; Naito M; Tamai H
Anticancer Res; 2001; 21(4A):2463-9. PubMed ID: 11724308
[TBL] [Abstract][Full Text] [Related]
8. Acquired cisplatin resistance in human ovarian cancer cells is associated with enhanced repair of cisplatin-DNA lesions and reduced drug accumulation.
Parker RJ; Eastman A; Bostick-Bruton F; Reed E
J Clin Invest; 1991 Mar; 87(3):772-7. PubMed ID: 1999494
[TBL] [Abstract][Full Text] [Related]
9. Correlation between cell killing by cis-diamminedichloroplatinum(II) in six mammalian cell lines and binding of a cis-diamminedichloroplatinum(II)-DNA antiserum.
Terheggen PM; Emondt JY; Floot BG; Dijkman R; Schrier PI; den Engelse L; Begg AC
Cancer Res; 1990 Jun; 50(12):3556-61. PubMed ID: 2340504
[TBL] [Abstract][Full Text] [Related]
10. Single step selection of cis-diamminedichloroplatinum(II) resistant mutants from a human ovarian carcinoma cell line.
McLaughlin K; Stephens I; McMahon N; Brown R
Cancer Res; 1991 Apr; 51(8):2242-5. PubMed ID: 1901242
[TBL] [Abstract][Full Text] [Related]
11. Cellular resistance to chloroethylnitrosoureas, nitrogen mustard, and cis-diamminedichloroplatinum(II) in human glial-derived cell lines.
Aida T; Bodell WJ
Cancer Res; 1987 Mar; 47(5):1361-6. PubMed ID: 3469016
[TBL] [Abstract][Full Text] [Related]
12. Relationship between platinum-DNA adduct formation and removal and cisplatin cytotoxicity in cisplatin-sensitive and -resistant human ovarian cancer cells.
Johnson SW; Swiggard PA; Handel LM; Brennan JM; Godwin AK; Ozols RF; Hamilton TC
Cancer Res; 1994 Nov; 54(22):5911-6. PubMed ID: 7954422
[TBL] [Abstract][Full Text] [Related]
13. Independent pathways of p53 induction by cisplatin and X-rays in a cisplatin-resistant ovarian tumor cell line.
Siddik ZH; Mims B; Lozano G; Thai G
Cancer Res; 1998 Feb; 58(4):698-703. PubMed ID: 9485023
[TBL] [Abstract][Full Text] [Related]
14. Enhanced cisplatin cytotoxicity by disturbing the nucleotide excision repair pathway in ovarian cancer cell lines.
Selvakumaran M; Pisarcik DA; Bao R; Yeung AT; Hamilton TC
Cancer Res; 2003 Mar; 63(6):1311-6. PubMed ID: 12649192
[TBL] [Abstract][Full Text] [Related]
15. Increased glutathione level is not involved in enhanced bleomycin sensitivity in cisplatin-resistant 2780CP cells.
Tanaka T; Kurokawa H; Matsuno K; Matsumoto S; Hayashida Y
Anticancer Res; 2008; 28(5A):2663-8. PubMed ID: 19035292
[TBL] [Abstract][Full Text] [Related]
16. Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells.
Pietras RJ; Fendly BM; Chazin VR; Pegram MD; Howell SB; Slamon DJ
Oncogene; 1994 Jul; 9(7):1829-38. PubMed ID: 7911565
[TBL] [Abstract][Full Text] [Related]
17. Antitumor activity and biochemical effects of aphidicolin glycinate (NSC 303812) alone and in combination with cisplatin in vivo.
O'Dwyer PJ; Moyer JD; Suffness M; Harrison SD; Cysyk R; Hamilton TC; Plowman J
Cancer Res; 1994 Feb; 54(3):724-9. PubMed ID: 8306334
[TBL] [Abstract][Full Text] [Related]
18. Enhanced host cell reactivation of damaged plasmid DNA in HeLa cells resistant to cis-diamminedichloroplatinum(II).
Chao CC; Lee YL; Cheng PW; Lin-Chao S
Cancer Res; 1991 Jan; 51(2):601-5. PubMed ID: 1898714
[TBL] [Abstract][Full Text] [Related]
19. Ormaplatin sensitivity/resistance in human ovarian cancer cells made resistant to cisplatin.
Parker RJ; Vionnet JA; Bostick-Bruton F; Reed E
Cancer Res; 1993 Jan; 53(2):242-7. PubMed ID: 8417816
[TBL] [Abstract][Full Text] [Related]
20. Lactacystin enhances cisplatin sensitivity in resistant human ovarian cancer cell lines via inhibition of DNA repair and ERCC-1 expression.
Li QQ; Yunmbam MK; Zhong X; Yu JJ; Mimnaugh EG; Neckers L; Reed E
Cell Mol Biol (Noisy-le-grand); 2001; 47 Online Pub():OL61-72. PubMed ID: 11936875
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
